Mar 20, 2025 · TCF-001 TRACK is an innovative clinical trial enrolling 400 patients with rare cancers or cancer of unknown primary. Through a remote consenting process, patients can fully enroll in the TRACK study from their homes, without traveling to a clinical trial site.

Driving precision medicine in rare cancers. Developed and launched by TargetCancer Foundation, TCF-001 TRACK is a fully remote clinical trial enrolling 400 patients with rare cancers or cancers of unknown primary.

TCF-001 TRACK is an innovative rare cancer clinical trial enrolling 400 patients with rare cancers or cancer of unknown primary. Through a remote consenting process, patients can fully enroll in the TRACK study from their homes, without traveling to a clinical trial site.

today the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study, an innovative trial that brings advances in precision medicine to people living with rare cancers and their treating physicians, right in their own communities.

May 28, 2021 · Novel “patient-centric” trials are needed, especially for rare cancers. TRACK is a decentralized, patient advocacy-initiated trial that aims to establish whether patients with rare tumors and cancer of unknown primary can benefit from matched molecular therapy as dictated by their CGP results.

Aug 6, 2020 · A new study sponsored by the non-profit TargetCancer Foundation (TCF) will leverage remote consent to recruit 400 people with rare forms of cancer with an eye toward providing these patients with effective precision treatments delivered by their own community-based physicians.

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Through the TCF-001 TRACK clinical trial, TargetCancer Foundation is directly impacting patients facing rare cancers today by providing them with personalized information to potentially inform treatments while simultaneously generating critical data to drive rare cancer research forward.

The TCF-001 TRACK clinical trial represents a cutting-edge approach in the field of precision oncology, specifically focusing on rare cancers and cancers of unknown primary. This trial is currently enrolling 400 patients using a remote consenting process.

To define the clinical characteristics of patients with variants in TCF20, we describe 27 patients, 26 of whom were identified via exome sequencing. We compare detailed clinical data with 17 previously reported patients.